-
公开(公告)号：US11965029B2
公开(公告)日：2024-04-23
申请号：US17339301
申请日：2021-06-04
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2866 , C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
2.发明授权公开(公告)号：US12060430B2
公开(公告)日：2024-08-13
申请号：US17332578
申请日：2021-05-27
Applicant: AMGEN INC.
Inventor： Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K39/3955 , A61K2300/00
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：US10336798B2
公开(公告)日：2019-07-02
申请号：US15625891
申请日：2017-06-16
Applicant: Amgen Inc.
Inventor： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC: A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C07K14/475 , C07K14/495 , C07K14/51 , A61K39/00
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US10227414B2
公开(公告)日：2019-03-12
申请号：US15601868
申请日：2017-05-22
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
公开(公告)号：US09862752B2
公开(公告)日：2018-01-09
申请号：US14908459
申请日：2014-07-31
Applicant: Amgen Inc.
Inventor： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Marissa Mock , Kenneth Walker
IPC: C07K14/00 , C07K14/475
CPC classification number: C07K14/475 , C07K2319/30
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
Patent Agency Ranking
公开(公告)号：US09382318B2
公开(公告)日：2016-07-05
申请号：US13897096
申请日：2013-05-17
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
Abstract translation: 本文描述的是与抗原结合蛋白相关的组合物和方法，其结合人ST2，包括抗体。 在具体实施方案中，本公开提供完全人抗-ST2抗体及其衍生物及其变体。 还提供了编码这种抗体和抗体片段，变体和衍生物的核酸。 此外，提供制备和使用这些抗体的方法，包括治疗和预防自身免疫性和炎症性疾病的方法。
-
公开(公告)号：US20140378665A1
公开(公告)日：2014-12-25
申请号：US14374885
申请日：2013-01-28
Applicant: AMGEN INC.
Inventor： Yumei Xiong , Yi Zhang , Jackie Zeqi Sheng , Agnes Eva Hamburger , Murielle Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC: C07K14/475
CPC classification number: C07K14/475 , A61K39/0005 , A61K2039/6056 , C07K2319/30
Abstract: GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Abstract translation: 提供GDF15多肽，包含GDF15的构建体及其突变体。 在各种实施方案中，GDF15多肽，包含GDF15的构建体及其突变体可用于治疗或改善代谢紊乱。 在各种实施方案中，代谢疾病或病症是2型糖尿病，肥胖症，血脂异常，升高的葡萄糖水平，升高的胰岛素水平和糖尿病性肾病。
-
8.发明授权公开(公告)号：US12252540B2
公开(公告)日：2025-03-18
申请号：US17332578
申请日：2021-05-27
Applicant: AMGEN INC.
Inventor： Junming Yie , Donghui Shi , David J. Lloyd , Jinghong Wang , Glenn N. Sivits, Jr. , Murielle M. Veniant-Ellison , Renee Komorowski , Neeraj Agrawal , Darren L. Bates , Brandon C. P. Clavette , Ian N. Foltz , Shu-yin Ho , Christopher Murawsky , Xiaoshan Min , Zhulun Wang
Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.
-
公开(公告)号：US11919953B2
公开(公告)日：2024-03-05
申请号：US17375958
申请日：2021-07-14
Applicant: AMGEN INC.
Inventor： Sue J. Sohn , Marissa Mock , Ian Nevin Foltz , Agnieszka Kielczewska , Kathy Manchulenko , Yannick Bulliard , Xiaoshan Min
CPC classification number: C07K16/2803 , A61P35/00 , C07K16/2818 , A61K2039/507 , C07K2317/21 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: Provided herein are TIGIT binding proteins, CD112R binding proteins, and combinations thereof. Also provided are compositions comprising TIGIT binding proteins and CD112R binding proteins, optionally further comprising PD-1 binding proteins. Related conjugates, fusion proteins, nucleic acids, vectors, host cells and kits are additionally provided. Further provided are pharmaceutical compositions comprising a TIGIT binding protein, CD112R binding protein, or a combination thereof, optionally, further comprising a PD-1 antigen binding protein, or a conjugate, fusion protein, nucleic acid, vector, or host cell, and a pharmaceutically acceptable carrier, diluent, or excipient, and methods of treating subjects in need thereof.
-
公开(公告)号：US09982054B2
公开(公告)日：2018-05-29
申请号：US15178652
申请日：2016-06-10
Applicant: Amgen Inc.
Inventor： Dirk E. Smith , Ian Foltz , Chadwick T. King , Ai Ching Lim , Rutilio Clark , Michael R. Comeau , Randal R. Ketchem , Donghui Shi , Xiaoshan Min , Zhulun Wang
CPC classification number: C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/51 , C07K2317/515 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/11
Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, including antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and deriviatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflammatory disorders.
-
-
-
-
-
-
-
-
-
Search Results
17
records
(took 0.021 seconds)
